Larimar Therapeutics appoints John B. Harlow, Jr. as president and COO

Larimar Therapeutics, Inc. has appointed John B. Harlow, Jr. as president and chief operating officer, effective immediately. Mr. Harlow, 51, most recently served as chief commercial officer at Esperion Therapeutics, Inc. Prior to that, he held various commercial leadership positions at Melinta Therapeutics, LLC, Baudax Bio, Inc., and Recro Pharma, Inc. He also worked at Endo, Inc., Shionogi, Inc., Pfizer, Inc., Novartis AG, and was an equity research analyst at Merrill Lynch.

Under his appointment, Mr. Harlow will receive an initial base salary of $560,000 per year, a $35,000 cash signing bonus, and an annual bonus with a target of 40% of his base salary. The appointment comes as the biotech company, with a market capitalization of $326 million, faces near-term challenges, with shares dropping 17% over the past week to trade at $3.14.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.